Maria Arantxa Horga, MD, serves as the Chief Medical Officer at Atea Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative antiviral therapeutics for life-threatening viral infections. Dr. Horga brings a wealth of experience in clinical development and medical affairs, particularly in the field of infectious diseases. She has a distinguished career that spans over two decades, during which she has held leadership positions at several prominent pharmaceutical companies, including Merck and Novartis. Throughout her career, Dr. Horga has been instrumental in advancing the development of numerous antiviral therapies. Her work has significantly contributed to the treatment landscape for viral infections, including hepatitis C and HIV. At Merck, she played a key role in the development and global launch of several blockbuster antiviral drugs. Her strategic vision and deep understanding of clinical development processes have been pivotal in guiding these drugs from early-stage research to market approval. Dr. Horga's achievements have earned her recognition within the medical and pharmaceutical communities, where she is respected for her expertise and dedication to improving patient outcomes. As Chief Medical Officer at Atea Pharmaceuticals, Dr. Horga oversees the clinical development strategy and execution of the company's pipeline, which includes novel treatments for diseases such as COVID-19 and hepatitis D. Her role involves leading a team of medical professionals and collaborating with external partners to ensure the successful progression of clinical trials. Dr. Horga's leadership is crucial in navigating the complex regulatory environment and in advancing Atea's mission to deliver transformative therapies to patients worldwide. Her commitment to excellence and her passion for addressing unmet medical needs continue to drive the company's efforts in the fight against viral diseases.